Item: 9.3.2

REPORT CLASSIFICATION	\checkmark	CATEGORY OF PAPER	\checkmark
Official	✓	Proposes specific action	
Official: Sensitive Commercial		Provides assurance	\checkmark
Official: Sensitive Personal		For information only	

BOARD 30 JULY 2024				
Report Title:	Quality and Safety Committee Highlight Report			
Purpose of report				

To provide the Board with a summary of the key points from the meeting of the Quality and Safety Committee held on 09 May 2024.

Key points

The Committee considered several issues and supporting papers at its meeting held on 09 May 2024 and the key points are summarised below.

- **Chairs discussion** The Chair invited members to share their views on what they would like to see discussed at the Committee in the coming months. An informal discussion took place under the headings of "what does quality and safety mean" and "what would the members like to see on the committee agenda".
- **Patient Story** A patient story was presented in relation to a daughter's account of her mother's experience of a palliative care and end of life pathway. The Committee noted that there was a lot of learning to take from this patient journey and highlighted the lack of continuity and leadership that had been observed throughout. Permission was requested and received to use the information from this section of the meeting to take these issues forward.
- Board Assurance Framework and Quality and Safety Risk Register The report provided the Committee with an update on the Board Assurance Framework (BAF) and an updated position on the current risks which align to the quality and safety portfolio for the reporting period 28 February 2024 to 19 April 2024.
- Annual Committee Report and Effectiveness Survey The Committee approved the draft annual review of the Committee for submission to Board in May.
- **Quality Strategy** The Quality Strategy was presented to the Committee following feedback from the Board development session. The Committee received and noted the quality strategy update, recognising that there was some ongoing engagement work and development to be undertaken to inform the next steps in the development of the strategy.
- Quality Report The report provided the Committee with oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South. Updates and assurance was provided on a number of areas including: Care Homes and Domiciliary Care; Learning from lives and deaths people with a learning disability and autistic people (LeDeR) reviews; Continuing Healthcare (CHC) continued pressures across all teams were reported due to ongoing staffing challenges relating to sickness and delays in recruitment

from the ICB 2.0 HR process; North and South area Quality and Safety subcommittees - approval from the committee was requested to merge place-based subcommittees for quality, to make a north and south subcommittee (replacing the current four area subcommittees).

The Board is asked to note that the approved minutes for the May meeting are not yet available due to the date of the Committee meeting in July being rescheduled to 31 July 2024 to enable quoracy to be achieved for the meeting. The minutes from the May meeting will be presented to Board at its next meeting for assurance following approval by the Committee.

Risks and issues

The Committee will continue to receive and review the corporate risks aligned to the quality and safety portfolio to provide assurance to the Board that the quality and safety risks contained within the corporate risk register reflect the current environment.

Assurances

The Committee also received several items for assurance including:

- Board Assurance Framework and Quality & Safety risk register
- Integrated Delivery Report providing an overview of quality and performance, highlighting any significant changes, areas of risk and mitigating actions.
- ICB quality exception report oversight of key quality themes, risks and exceptions outlined in the ICB Area Quality reports for Central, North, North Cumbria and South.
- Involvement and engagement update report
- Healthcare acquired infection subcommittee minutes
- Special Educational Needs and Disabilities subcommittee minutes
- Safeguarding subcommittee minutes
- Medicines subcommittee minutes
- Area quality and safety subcommittee minutes

Recommendation/action required

The Board is asked to note the key highlights from the meeting held on 09 May 2024 and that the approved minutes from this meeting will be presented to the next meeting of the Board for assurance.

Acronyms and abbreviations explained

As described in the report.

Sponsor/approving executive director	Sir Pali Hungin, Chair of Quality and Safety Committee and Independent Non- Executive Member David Purdue, Chief Nurse, AHP and People Officer			
Date approved by executive director	16 July 2024			
Report author	Neil Hawkins, Strategic Head of Corporate Governance			
Link to ICP strategy priorities (please tick all that apply)				
Longer and Healthier Lives		\checkmark		
Fairer Outcomes for All		\checkmark		
Better Health and Care Services		\checkmark		
Giving Children and Young People the Best Start in Life				

Relevant legal/statutory issues

Note any relevant Acts, regulations, nation	onal guideline	s etc				
Any potential/actual conflicts of interest associated with the paper? (please tick)	Yes	No	✓	N/A		
If yes, please specify						
Equality analysis completed (please tick)	Yes	No		N/A	~	
If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick)	Yes	No		N/A	~	
Key implications:		<u>.</u>				
Are additional resources required?	None at this stage					
Has there been/does there need to be appropriate clinical involvement?	Appropriate clinical representation within the membership of the Committee. Terms of reference to include representation from Nursing Directors and Medical Directors.					
Has there been/does there need to be any patient and public involvement?	N/A.					
Has there been/does there need to be partner and/or other stakeholder engagement?	N/A					
Has there been/does there need to be appropriate finance or digital involvement?	N/A					